1 / 7

Immune Checkpoint Inhibitors Market

The immune checkpoint inhibitors market was negatively impacted by the COVID-19 pandemic. Owing to decline in number of cancer patient visits in hospitals and clinics for immune checkpoint inhibitors therapies which lead to decline in the demand of immune checkpoint inhibitors products. For instance, according to AstraZenca PLC, Opidivo (immune checkpoint inhibitor) registered a 5.6 % decline in

Sanyukta_K
Download Presentation

Immune Checkpoint Inhibitors Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Download Report Sample

  2. The global immune checkpoint inhibitors market was valued at $29,803.71 million in 2020, and is projected to reach $1,40,890.10 million by 2030, registering a CAGR of 16.8% from 2021 to 2030. Checkpoint inhibitor is a type of drug used in immunotherapy, which helps block the proteins present on tumor cells as they affect functioning of the immune system. Immune checkpoint inhibitor drugs block different checkpoint proteins including CTLA-4 (cytotoxic T lymphocyte associated protein 4), PD-1 (programmed cell death protein 1), and PD-L1 (programmed death ligand 1). Immune checkpoint inhibitor targets checkpoint proteins and assists the immune system to recognize and attack cancer cells.  Download Report Sample @ https://www.alliedmarketresearch.com/immune-check-point-inhibitors-market Immune Checkpoint Inhibitors Market Download Report Sample

  3. The key factors driving growth of Immune Checkpoint Inhibitors market growth are attributed to increase in incidences of different forms of cancer, surge in awareness of checkpoint inhibitors for treatment of cancer, higher number of R&D studies, and surge in adoption of immune checkpoint inhibitor drugs. In addition, growth in geriatric population and technological advancements in screening & diagnosis of cancer further drives the market growth. However, high cost associated with immune checkpoint inhibitors is projected to impede the market growth. The immune checkpoint inhibitors market is segmented on the basis of type, application, and region. On the basis of, the market is classified as CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor, and others. According application, it is categorized into lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/3723 Immune Checkpoint Inhibitors Market Download Report Sample

  4. By region, the Immune checkpoint inhibitors market is analyzed across North America, Asia-Pacific, Europe, and LAMEA. North America dominated the market in 2020, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. The research activities for immune checkpoints inhibitors are soaring in North America due to significant infrastructure for developmental research, availability of substantial research funds and growing government initiatives towards immune checkpoint inhibitors are anticipated to drive the market growth. Customization request @ https://www.alliedmarketresearch.com/request-for-customization/3723 Immune Checkpoint Inhibitors Market Download Report Sample

  5. The Major Key Players Are: • AstraZeneca PLC • Bristol-Myers Squibb Company • Eli Lilly and Company (ARMO Biosciences.) • GlaxoSmithKline PLC • F. Hoffmann-La Roche Ltd. (Genentech Inc.,) • Sanofi • Merck & Co., Inc. • Merck KGaA (EMD Serono Inc.) • BeiGene Ltd • Shanghai Jhunsi Biosciences Ltd. Immune Checkpoint Inhibitors Market Download Report Sample

  6. Key Benefits for Stakeholders • This report provides a detailed quantitative analysis of the current Immune checkpoint inhibitors market trends and forecast estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.  • An in-depth market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans. • A comprehensive analysis of factors that drive and restrain the growth of the global is provided. • The projections in this report are made by analyzing the current trends and future market potential from 2021 to 2030, in terms of value. • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves. • Key market players within the Immune checkpoint inhibitors market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of the Immune checkpoint inhibitors market. Immune Checkpoint Inhibitors Market Download Report Sample

  7. Contact: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States Toll Free (USA/Canada): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1-855-550-5975 help@alliedmarketresearch.com Web: https://www.alliedmarketresearch.com Immune Checkpoint Inhibitors Market Download Report Sample

More Related